Clinical Trial Update: To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SAR153191 (REGN88) added to other rheumatoid arthritis therapies in patients not responding to anti-TNF treatment has completed, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• SAR153191 (REGN88) (SAR153191)

Snippet

Sponsor: Sanofi | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-08-08